ישראל - עברית - Ministry of Health

novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.

ישראל - עברית - Ministry of Health

novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.

ישראל - עברית - Ministry of Health

novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

ישראל - עברית - Ministry of Health

novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

ישראל - עברית - Ministry of Health

omrix biopharmaceuticals - calcium chloride 5.6 - 6.2 mg; human thrombin 800 - 1200 iu - solution - thrombin - as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standart surgical techniques is ineffective or impractical.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - קפסולות - paricalcitol 1 mcg - paricalcitol - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

ישראל - עברית - Ministry of Health

omrix biopharmaceuticals - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 50 mg/ml mg/ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy * primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinemia or hypogammaglobulinemia) * myeloma or chronic lymphocytic leukemia (cll) with severe secondary hypogammaglobulinemia and recurrent infections. * children with congenital aids and recurrent infections - immunomodulation * idiopathic thrombocytopenic purpura (itp) * guillain barre syndrome * kawasaki disease - allogenic bone marrow transplantation

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 3.75 mg - leuprorelin